Welcome to our dedicated page for Olema Pharmaceuticals news (Ticker: OLMA), a resource for investors and traders seeking the latest updates and insights on Olema Pharmaceuticals stock.
Olema Pharmaceuticals, Inc. (Olema Oncology, Nasdaq: OLMA) is a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer and other endocrine-driven cancers. The news flow around OLMA reflects its active clinical development program, capital markets activity, and ongoing corporate updates.
Investors and followers of Olema’s news can expect frequent updates on its lead product candidate, palazestrant (OP-1250), an orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) being evaluated in ER+/HER2- metastatic breast cancer. Company announcements include progress in pivotal Phase 3 trials such as OPERA-01 and OPERA-02, data presentations from Phase 1b/2 studies of palazestrant in combination with ribociclib, and details on additional Phase 1/2 combination studies with agents like palbociclib, alpelisib, everolimus, and atirmociclib.
Olema’s news stream also covers pipeline developments for OP-3136, a KAT6 inhibitor in Phase 1 clinical evaluation as monotherapy and in combination with fulvestrant and palazestrant in advanced solid tumors. Regulatory and collaboration milestones, such as clinical trial agreements with Pfizer to study palazestrant plus atirmociclib, are disclosed through press releases and SEC filings.
In addition, Olema regularly reports financial and operating results, underwritten public offerings of common stock under its shelf registration on Form S-3, and inducement grants of stock options to new employees under its 2022 Inducement Plan. The company also announces participation in healthcare and investor conferences, where it presents updates on its clinical programs and strategy. Readers who follow OLMA news gain insight into trial progress, collaboration agreements, financing activities, and other corporate events that shape Olema’s development as a clinical-stage oncology company.
Olema Oncology (Nasdaq: OLMA) will present a trial-in-progress poster for the Phase 3 OPERA-02 study at the 2025 San Antonio Breast Cancer Symposium (SABCS 2025) on December 12, 2025.
The randomized, double-blind, active-controlled trial compares palazestrant plus ribociclib versus letrozole plus ribociclib as first-line therapy for ER+, HER2- advanced or metastatic breast cancer. Poster: Abstract 264, Presentation PS5-12-18, 12:30pm–2:00pm CT. A poster copy will be posted on Olema's publications page per SABCS embargo policy.
Olema Oncology (Nasdaq: OLMA) reported updated Phase 1b/2 data for palazestrant plus ribociclib in ER+/HER2- advanced or metastatic breast cancer presented at ESMO 2025 on October 20, 2025.
Key clinical readouts: in the 120 mg palazestrant cohort (n=56, median follow-up >19 months) median PFS was 15.5 months overall; among patients with prior CDK4/6 inhibitor therapy median PFS was 12.2 months (9.2 months for ESR1 wild-type; 13.8 months for ESR1 mutant). Across 72 patients, the combination showed favorable tolerability, no new safety signals, and no drug-drug interactions. Data support the ongoing Phase 3 OPERA-02 trial in the frontline setting.
Olema Oncology (Nasdaq: OLMA) granted stock options to three new employees for an aggregate of 77,000 shares, effective October 1, 2025, approved under the company's 2022 Inducement Plan as required by Nasdaq Listing Rule 5635(c)(4).
The options vest over four years (25% after one year, then 36 equal monthly installments), have a 10-year term, and an exercise price of $11.04 per share (equal to the last reported sale price on Nasdaq on October 1, 2025). Olema disclosed the awards to comply with Nasdaq rules governing inducement grants.
Olema Oncology (Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer, has granted stock options to four new employees under its 2022 Inducement Plan. The grants total 124,000 shares with an exercise price of $6.47 per share.
The stock options feature a 4-year vesting schedule with 25% vesting after the first year and the remaining portion vesting monthly over three years. The options have a 10-year term and were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Olema Oncology (Nasdaq: OLMA) has announced a new clinical trial collaboration with Pfizer (NYSE: PFE) to evaluate the combination of palazestrant and atirmociclib in patients with ER+/HER2- metastatic breast cancer.
The Phase 1b/2 study will assess the safety and combinability of Olema's palazestrant with Pfizer's investigational CDK4 inhibitor atirmociclib in approximately 35 patients, with trial initiation expected in H2 2025. Results will inform a potential pivotal Phase 3 trial in frontline metastatic breast cancer.
Under the agreement, Pfizer will supply atirmociclib while Olema leads the study. Both companies will jointly own clinical data and inventions, with Olema retaining full global commercial rights to palazestrant.
Olema Oncology (NASDAQ:OLMA), a clinical-stage biopharmaceutical company specializing in targeted therapies for breast cancer, has announced its participation in five major investor conferences in September 2025.
The company will present at Citi's Biopharma Back to School Conference (Sept 2), Wells Fargo Healthcare Conference (Sept 3), Cantor Global Healthcare Conference (Sept 4), Morgan Stanley Global Healthcare Conference (Sept 8), and H.C. Wainwright Global Investment Conference (Sept 9). All conferences will take place in Boston and New York, featuring a mix of presentations and fireside chats.
Investors can access live webcasts and recordings through Olema's investor relations website at ir.olema.com.
Olema Oncology (Nasdaq: OLMA) has reported its Q2 2025 financial results and provided key operational updates. The company has selected 90 mg once-daily palazestrant for Part 2 of the OPERA-01 Phase 3 trial and the OPERA-02 Phase 3 trial in combination with ribociclib for breast cancer treatment.
Key financial metrics include $361.9 million in cash and equivalents, and a net loss of $43.8 million for Q2 2025, compared to $30.4 million in Q2 2024. R&D expenses increased to $43.9 million, primarily due to a $10 million milestone payment to Aurigene and increased clinical development activities.
The company expects to present mature data from the Phase 1b/2 study at ESMO 2025, initiate OPERA-02 in Q3 2025, and report OPERA-01 top-line data in H2 2026.
Olema Oncology (Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on breast cancer therapies, has granted stock options to four new employees. The grants total 130,000 shares of common stock with an exercise price of $5.33 per share.
The stock options, approved under the Company's 2022 Inducement Plan, will vest over four years, with 25% vesting after the first year and the remainder vesting monthly over three years. The options have a 10-year term and were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Olema Oncology (Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on breast cancer therapies, has granted stock options to four new employees. The grants total 154,500 shares of common stock with an exercise price of $4.37 per share.
The stock options, approved under the company's 2022 Inducement Plan, will vest over four years, with 25% vesting in the first year and the remainder vesting monthly over three years. The options have a 10-year term and were granted in accordance with Nasdaq Listing Rule 5635(c)(4).